Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A role for fMRI in optimizing CNS drug development.

David Borsook1, Lino Becerra, Richard Hargreaves

  • 1Imaging Center for Drug Development (ICD), Mclean Hospital, Department of Psychiatry, USA. dborsook@mclean.harvard.edu

Nature Reviews. Drug Discovery
|April 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal cognitive assessment using the Cumulus NeuLogiq platform in amyotrophic lateral sclerosis and frontotemporal dementia.

Scientific reports·2026
Same author

Virtual Reality-Based Pain Modulation in Subacute Musculoskeletal Injury: Functional Near-Infrared Spectroscopy Study of Neural and Behavioral Correlates.

JMIR serious games·2026
Same author

Accelerating Medicines Partnership® Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

A cross-sectional analysis of brain structure, pain behaviors, and mental health in persons with surgically confirmed endometriosis.

Communications biology·2025
Same author

Neural evidence for the effects of behavioral memory updating following fear conditioning.

Communications psychology·2025
Same author

Allostatic load and pain: instability of a bio-social ecosystem.

Pain·2025

Functional magnetic resonance imaging (fMRI) can enhance central nervous system (CNS) drug discovery. This technique optimizes decision-making, improving success rates and reducing development risks and costs.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medical Imaging

Background:

  • Drug development for central nervous system (CNS) disorders requires balancing speed, agility, and risk.
  • The complexity of the brain, with multiple neurotransmitters and intersecting circuits, presents challenges in CNS drug discovery.
  • Developing novel therapeutics targeting unprecedented CNS mechanisms necessitates methods to assess functional consequences.

Purpose of the Study:

  • To explore the potential of functional magnetic resonance imaging (fMRI) techniques in transforming CNS drug development.
  • To highlight how fMRI can provide key metrics for early decision-making in the drug discovery pipeline.
  • To demonstrate how fMRI can improve success rates while reducing risks, development times, and costs.

Main Methods:

Related Experiment Videos

  • Utilizing advanced functional magnetic resonance imaging (fMRI) to dynamically examine brain systems and their functional activation.
  • Applying fMRI as a metric to assess the functional consequences of CNS target interactions.
  • Integrating fMRI data into the early stages of CNS drug discovery and development.

    • Main Results:

    • fMRI offers a promising approach to dynamically assess brain system activation relevant to CNS disorders.
    • The application of fMRI can provide crucial data for evaluating therapeutic potential early in development.
    • fMRI can serve as a key metric to increase confidence in decision-making for CNS drug candidates.

    Conclusions:

    • Functional magnetic resonance imaging (fMRI) holds significant promise for optimizing central nervous system (CNS) drug discovery.
    • By providing dynamic functional insights, fMRI can enhance early decision-making, thereby improving the probability of success.
    • Implementing fMRI can lead to reduced risks, development times, and costs in CNS therapeutic development.